BIOSOLVE-IV Registry one-year follow up data, analyzing 2,066 patients showed Superiority of BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) versus Abbott’s Absorb Bioresorbable Vascular Scaffold in Scaffold Thrombosis*
Superiority of the Magmaris® sirolimus-eluting bioresorbable magnesium scaffold with regard to probable or definite scaffold thrombosis compared to a historical control group of Absorb scaffold data was demonstrated for the first time in a prospective, powered secondary endpoint in the BIOSOLVE-IV trial.1 The new full-cohort one-year results were presented at TCT and confirm the safety and performance of the Magmaris® scaffold in a larger cohort. Of particular note is the target lesion failure2 rate of 5.0% and a definite / probable scaffold thrombosis rate of 0.8% at 12 months, confirming the very good safety profile from the first cohort with 1,075 patients. The new data was presented by Prof. Dr. Johan Bennett, Coronary Interventionalist at the University Hospitals Leuven in Belgium.3